Flowchart of the selection of study participants.
- In Ah Choi (6185000)
- Jeong Seok Lee (2236030)
- Yeong Wook Song (219636)
- Eun Young Lee (219648)
Publication date
January 2019
DOI Publisher
Public Library of Science (PLoS)Abstract
*Methotrexate, sulfasalazine, hydroxychloroquine, leflunomide, tacrolimus, bucillamine, mizoribine, cyclosporine, infliximab, etanercept, adalimumab, golimumab, abatacept, tocilizumab, rituximab, and tofacitinib. **Systemic connective tissue disorders (International Classification of Diseases 10th revision [ICD-10] code: M30-M36), ankylosing spondylitis (ICD-10 code: M45), psoriatic and enteropathic arthropathies (ICD-10 code: M07), or juvenile arthritis (ICD-10 code: M08). RA, rheumatoid arthritis; DMARD, disease-modifying anti-rheumatic drug.</p
Add to ORKG